Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646865 | 1.00 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL30627708 | 0.91 | FOLH1 (0.43) | FOLH1 | |
| SCHEMBL22466340 | 0.85 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL22466369 | 0.85 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL22466370 | 0.85 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL22466339 | 0.85 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL22228923 | 0.85 | FOLH1 (0.42) | FOLH1 | |
| SCHEMBL23646869 | 0.80 | FOLH1 (0.49) | FOLH1 | |
| SCHEMBL1077623 | 0.79 | FOLH1 (0.47) | FOLH1 | |
| SCHEMBL1077625 | 0.79 | FOLH1 (0.47) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813340-B2 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA3, PSMA2 | FOLH1 6/4885 |
| US-11813340-B2 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | PSMA1, PSMA3, PSMA2 | FOLH1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.